Fabrication and characterization of polycaprolactone/cellulose acetate blended nanofiber mats containing sericin and fibroin for biomedical application

Polycaprolactone/cellulose acetate blended nanofiber mats containing sericin and fibroin were fabricated by electrospinning process to study the effect of sericin and fibroin on the physical and structural properties, wettability, degradability, elastic modulus, cell adhesion, and cell cytotoxicity of the electrospun nanofibers. Polycaprolactone/cellulose acetate solution was prepared with different percentage ratio of sericin and fibroin to be the running solution. Nanofibers were spun at fixed solution flow rate, flying distance, and operating voltage. The diameter of the obtained nanofibers linearly increases with the increasing of the sericin ratio. The derivative structures of polycaprolactone, cellulose acetate, sericin, and fibroin of the obtained nanofibers were confirmed by FTIR analysis. All acquired nanofibers show superhydrophilicity with adequate time of degradation for L-929 cell adhesion and growth. More elasticity is gained when the sericin ratio decreases. Moreover, all fibers containing sericin/fibroin reveal more elasticity, cell adhesion, and cell growth than that with only polycaprolactone/cellulose acetate. Greater cell adhesion and growth develop when the sericin ratio is lower. All the fabricated nanofibers are low toxic to the cells. Fibers with a mixture of sericin and fibroin at 2.5:2.5 (% w/v) are the most promising and suitable for further clinical development due to their good results in each examination. The novelty found in this study is not only making more value of the sericin, silk industrial waste, and the fibroin, but also getting the preferable biomaterials, scaffold prototype, with much greater mechanical property and slower degradation, which are required and appropriate for cell attachment and proliferation of cell generation process, compared to that obtaining from polycaprolactone/cellulose acetate or sericin/fibroin nanofibers.